Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
|
|
|
- Derrick Cooper
- 6 years ago
- Views:
Transcription
1 Effective January 1, 2018 codes, behaviors and terms are site specific Status /N 8010/3 Urachal carcinoma (C65.9, C66.9, C67. _, C68._) 8013/3 Combined large cell neuroendocrine carcinoma (C34. _, C37.9) 8023/3 Midline carcinoma of children and young adults with NUT rearrangement (C30.0, C31.9, C34. _) 8023/3 NUT carcinoma (C30.0, C31.9, C34. _) 8023/3 NUT midline (C30.0, C31.9, C34. _) 8041/3 High grade neuroendocrine carcinoma (C54. _, C55.9) 8041/3 Neuroendocrine carcinoma, poorly differentiated (C50. _) 8041/3 Small cell carcinoma pulmonary type (C56.9) 8044/3 Small cell carcinoma, hypercalcemic type (C56.9) 8054/3 Condylomatous carcinoma (C60.0 C60.2, C60.9) Cases diagnosed prior to 1/1/2018 use code 8051/3 All other sites use 8051/ forward 8054/3 Warty carcinoma (C60.0 C60.2, C60.9) Cases diagnosed prior to 1/1/2018 use code 8051/3 All other sites use 8051/ forward 8071/2 Differentiated penile intraepithelial neoplasia (C60. _) N Not reportable for /2 Differentiated type vulvar intraepithelial neoplasia (C51. _) N Not reportable for /3 Squamous cell carcinoma, HPV positive (C01.9, C10.2, C10.3, C10.8, C10.9, C31.0 C31.3, C31.9)
2 8086/3 Squamous cell carcinoma, HPV negative (C01.9, C10.2, C10.3, C10.8, C10.9, C31.0 C31.3, C31.9) 8120/3 Clear cell (glycogen rich) urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) /N 8120/3 Lipid rich urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) 8120/3 Microcystic urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) 8120/3 Nested urothelial carcinoma (C65.9, C66.9, C67. _, C68. _) 8120/3 Squamotransitional cell carcinoma (C53. _) 8120/3 Urothelial carcinoma with divergent differentiation (C65.9, C66.9, C67. _, C68. _) 8120/3 Urothelial carcinoma with squamous differentiation (C65.9, C66.9, C67. _, C68. _) 8120/3 Urothelial carcinoma with trophoblastic differentiation (C65.9, C66.9, C67. _, C68. _) 8140/3 Minimally invasive adenocarcinoma, NOS (C34. _) 8140/3 Acinar adenocarcinoma (C61.9 ONL) For prostate only, do not use 8550/3 8140/3 Endocervical adenocarcinoma usual type (C53. _) 8144/3 Enteric adenocarcinoma (C34.0, C67. _, C65.9, C66.9, C68. _) 8144/3 Intestinal type adenocarcinoma (C30.0, C53. _) 8144/3 Mucinous carcinoma, intestinal type (C53. _) 8158/1 ACTH producing tumor N 8158/1 Endocrine tumor, functioning, NOS N 8163/3 Adenocarcinoma, pancreatobiliary type (C24.1) Cases diagnosed prior to 1/1/2018 use code 8255/3 8163/3 Pancreatobiliary type carcinoma (C24.1) Cases diagnosed prior to 1/1/2018 use code 8255/3
3 /N 8200/3 Thymic carcinoma with adenoid cystic carcinoma like features (C37.9) 8213/3 Serrated adenocarcinoma (C18.0, C18.2, C18.9, C19.9, C20.9) 8246/3 Neuroendocrine tumor, well differentiated (C50. _) 8250/2 Adenocarcinoma in situ, non mucinous (C34. _) 8250/3 Lepidic adenocarcinoma (C34. _) 8250/3 Lepidic predominant adenocarcinoma (C34. _) 8253/2 Adenocarcinoma in situ, mucinous (C34. _) Important note: lung primaries ONL: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for insitu adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 8253/3 Invasive mucinous adenocarcinoma (C34. _) Important note: lung primaries ONL: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for insitu adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 8254/3 Mixed invasive mucinous and non mucinous adenocarcinoma (C34. _)
4 /N 8256/3 Minimally invasive adenocarcinoma, non mucinous (C34. _) 8257/3 Minimally invasive adenocarcinoma, mucinous (C34. _) 8263/3 Endometrioid adenocarcinoma, villoglandular (C54. _, C55.9) 8263/3 Villoglandular carcinoma (C53. _) 8265/3 Micropapillary adenocarcinoma (C34. _) Cases diagnosed prior to 1/1/2018 use code 8507/ is not valid for C50._. Use 8507 for micropapillary adenocarcinoma in breast primaries 8265/3 Micropapillary carcinoma, NOS (C18. _, C19.9, C20.9, C34. _) Cases diagnosed prior to 1/1/2018 use code 8507/ is not valid for C50._. Use 8507 for micropapillary adenocarcinoma in breast primaries 8311/3 Hereditary leiomyomatosis & RCC associated renal cell carcinoma (C64.9) 8311/3 MiT family translocation renal cell carcinoma (C64.9) 8312/3 Renal cell carcinoma, unclassified (C64.9) 8316/3 Acquired cystic disease associated renal cell carcinoma (RCC) (C64.9) 8316/3 Tubulocystic renal cell carcinoma (C64.9) 8339/3 Follicular thyroid carcinoma (FTC), encapsulated angioinvasive (C73.9)
5 /N 8343/2 Non invasive EFVPTC (C73.9) Cases diagnosed 1/1/2017 forward 8343/2 Non invasive encapsulated follicular variant of papillary thyroid carcinoma (non invasive EFVPTC) (C73.9) Cases diagnosed 1/1/2017 forward 8343/2 Non invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) (C73.9) Cases diagnosed 1/1/2017 forward 8343/2 Non invasive FTP (C73.9) Cases diagnosed 1/1/2017 forward 8343/3 Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS) (C73.9) Cases diagnosed 1/1/2017 forward 8343/3 Invasive encapsulated follicular variant of papillary thyroid carcinoma Cases diagnosed 1/1/2017 forward (invasive EFVPTC) (C73.9) 8380/2 Atypical hyperplasia/endometrioid intraepithelial neoplasm (C54. _, N Not reportable for 2018 C55.9) 8441/2 Serous endometrial intraepithelial carcinoma (C54. _, C55.9) 8441/2 Serous tubal intraepithelial carcinoma (C57.0) 8453/2 Intraductal papillary mucinous neoplasm with high grade dysplasia (C25. _) 8453/3 Intraductal papillary mucinous neoplasm (IPMN) with an associated invasive carcinoma (C25. _) 8460/2 Non invasive low grade serous carcinoma (C56.9) 8460/2 Serous borderline tumor micropapillary variant (C56.9) N Not reportable for /3 Low grade serous carcinoma (C48. _, C56.9, C57.0, C57.1 C57.3) 8461/3 High grade serous carcinoma (C48. _, C56.9, C57.0, C57.1 C57.3)
6 /N 8470/3 Mucinous cystic tumor with associated invasive carcinoma (C25. _) 8474/3 Seromucinous carcinoma (C56.9) 8480/1 Low grade appendiceal mucinous neoplasm (C18.1) N 8480/3 Mucinous tubular and spindle cell carcinoma (C64.9) 8482/3 Mucinous carcinoma, gastric type (C53. _) 8500/2 Low grade cribriform cystadenocarcinoma (LGCCC) (C06.9, C08.9) 8500/2 Mammary carcinoma, in situ (C50. _) 8500/2 Non invasive mammary carcinoma (C50. _) 8500/3 Invasive carcinoma of no special type (C50. _) 8500/3 Invasive carcinoma, NST (C50. _) 8500/3 Invasive mammary carcinoma (C50. _) 8500/3 Salivary duct carcinoma (C06.9, C08.9) 8503/2 Intraductal papilloma with ductal carcinoma in situ (C50. _) 8503/2 Intraductal tubulopapillary neoplasm (C25. _) 8503/3 Intracystic papillary neoplasm with associated invasive carcinoma 8504/2 Encapsulated papillary carcinoma (C50. _) 8504/3 Encapsulated papillary carcinoma with invasion (C50. _) 8507/3 Invasive micropapillary carcinoma (C50. _) For sites other than C50. _, see 8265/3 8509/2 Solid papillary carcinoma in situ (C50. _) 8509/3 Solid papillary carcinoma with invasion (C50. _) 8510/3 Renal medullary carcinoma (C64.9) 8519/2 Pleomorphic lobular carcinoma in situ (C50. _) rule F DOES NOT APPL to code Invasive pleomorphic
7 /N lobular carcinoma is coded 8520/3 8520/2 Intraductal papilloma with lobular carcinoma in situ (C50. _) 8520/3 Invasive lobular carcinoma (C50. _) 8520/3 Invasive lobular carcinoma, alveolar type (C50. _) 8520/3 Invasive lobular carcinoma, solid type (C50. _) 8520/3 Invasive lobular carcinoma, tubulolobular variant (C50. _) 8520/3 Pleomorphic lobular carcinoma (C50. _) 8520/3 Tubulolobular carcinoma (C50. _) 8550/3 Acinar cell carcinoma Excludes C61.9 see 8140/3 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3 8552/3 Mixed acinar ductal carcinoma Cases diagnosed prior to 1/1/2018 use code 8523/3 8570/3 Endometrioid carcinoma with squamous differentiation (C54. _, C55.9) 8570/3 Low grade adenosquamous carcinoma (C50. _) 8571/3 Carcinoma with chondroid differentiation (C50. _) 8571/3 Carcinoma with osseous differentiation (C50. _) 8571/3 Metaplastic carcinoma with chondroid differentiation (C50. _) 8571/3 Metaplastic carcinoma with osseous differentiation (C50. _) 8572/3 Acinar adenocarcinoma, sarcomatoid (C61.9) 8572/3 Fibromatosis like metaplastic carcinoma (C50. _) 8574/3 Adenocarcinoma admixed with neuroendocrine carcinoma (C53. _) 8575/3 Carcinoma with other types mesenchymal differentiation (C50. _)
8 /N 8575/3 Metaplastic carcinoma of no special type (C50. _) 8575/3 Metaplastic carcinoma with other types mesenchymal differentiation (C50. _) 8594/1 Mixed germ cell sex cord stromal tumor, unclassified (C48.2, C56.9, N C57.9) 8620/3 Adult granulosa cell tumor (C56.9 ONL) N Not reportable for 2018 cases 8714/3 Malignant perivascular epithelial cell tumor 8714/3 PEComa, malignant 8714/3 Perivascular epithelioid cell tumor, malignant 8720/3 Meningeal melanoma (C70. _, C71._) 8801/3 Undifferentiated spindle cell sarcoma 8802/3 Undifferentiated pleomorphic sarcoma 8803/3 Undifferentiated round cell sarcoma 8804/3 Undifferentiated epithelioid sarcoma 8805/3 Undifferentiated uterine sarcoma 8811/1 Myxoinflammatory fibroblastic sarcoma (MIFS) (C49. _) N 8815/0 Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS) (C71. _) for CNS code/ 8815/1 Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS) (C71. _) for CNS ONL 8815/3 Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS) (C71. _) 8825/3 Low grade myofibroblastic sarcoma (C01.9, C02. _, C06.9, C49._) 8825/3 Myofibroblastic sarcoma
9 /N 8830/3 Malignant fibrous histiocytoma (MFH) of bone 8830/3 Undifferentiated high grade pleomorphic sarcoma 8832/3 Fibrosarcomatous dermatofibrosarcoma protuberans 8840/3 Low grade fibromyxoid sarcoma 8840/3 Sclerosing epithelioid fibrosarcoma 8842/3 Ossifying fibromyxoid tumor, malignant (C49. _) 8842/3 Pulmonary myxoid sarcoma with EWSR1 CREB1 translocation (C34. _) 8912/3 Sclerosing rhabdomyosarcoma 8933/3 Mullerian adenosarcoma (C54. _, C55.9) 8975/1 Calcifying nested epithelial stromal tumor (C22.0) N 8983/3 Adenomyoepithelioma with carcinoma (C50. _) 8990/3 Phosphaturic mesenchymal tumor, malignant 9020/3 Periductal stromal tumor, low grade (C50. _) 9045/3 Biphenotypic sinonasal sarcoma (C30.0, C31.0 C31.3, C31.8, C31.9) 9086/3 Germ cell tumors with associated hematological malignancy (C37.9) 9110/3 Adenocarcinoma of rete ovarii (C56.9) 9133/3 Epithelioid hemangioendothelioma 9137/3 Intimal sarcoma 9137/3 Pulmonary artery intimal sarcoma 9187/3 Low grade central osteosarcoma (C40. _, C41._) 9187/3 Low grade intramedullary osteosarcoma (C40. _, C41._)
10 /N 9220/3 Chondrosarcoma grade II/III (grade 2/3) 9302/3 Ghost cell odontogenic carcinoma (C41.0, C41.1) 9341/3 Clear cell odontogenic carcinoma (C41.0, C41.1) 9382/3 Anaplastic oligoastrocytoma (C71. _) 9382/3 Oligoastrocytoma, NOS (C71. _) 9385/3 Diffuse midline glioma, H3 K27M mutant (C71._) 9395/3 Papillary tumor of pineal region (C75.3) Cases diagnosed prior to 1/1/2018 use code 9361/3 9396/3 Ependymoma, RELA fusion positive (C71. _) 9400/3 Diffuse astrocytoma, IDH mutant (C71. _) 9400/3 Diffuse astrocytoma, IDH wildtype (C71. _) 9401/3 Anaplastic astrocytoma, IDH mutant (C71. _) 9401/3 Anaplastic astrocytoma, IDH wildtype (C71. _) 9424/3 Anaplastic pleomorphic xanthroastrocytoma (C71. _) 9425/3 Pilomyxoid astrocytoma (C71._) Cases diagnosed prior to 1/1/2018 use code 9421/3 9431/1 Angiocentric glioma (C71._) Cases diagnosed prior to 1/1/2018 use code 9380/1 9432/1 Pituicytoma (C75.1) Cases diagnosed prior to 1/1/2018 use code 9380/1 9440/3 Epithelioid glioblastoma (C71._) 9440/3 Glioblastoma, IDH wildtype (C71._) 9445/3 Glioblastoma, IDH mutant (C71._) 9450/3 Oligodendroglioma, IDH mutant and 1p/19q codeleted (C71._)
11 9451/3 Anaplastic oligodendroglioma, IDH mutant and 1p/19q codeleted (C71. _) /N 9470/3 Medulloblastoma, classic 9471/3 Medulloblastoma, SHH activated and TP53 wildtype (C71. _) 9475/3 Medulloblastoma, WNT activated (C71. _) 9476/3 Medulloblastoma, SHH activated and TP53 mutant (C71. _) 9477/3 Medulloblastoma, group 3 (C71. _) 9477/3 Medulloblastoma, group 4 (C71. _) 9477/3 Medulloblastoma, non WNT/non SHH (C71. _) 9478/3 Embryonal tumor with multilayered rosettes C19MC altered (C71. _) 9478/3 Embryonal tumor with multilayered rosettes, NOS (C71. _) 9508/3 CNS Embryonal tumor with rhabdoid features (C71. _) 9508/3 Embryonal tumor with rhabdoid features (C71._) 9509/1 Diffuse leptomeningeal glioneuronal tumor (C71. _) 9509/1 Papillary glioneuronal tumor (C71. _) Cases diagnosed prior to 1/1/2018 use code 9505/1 9509/1 Rosette forming glioneuronal tumor (C71. _) 9542/3 Epithelioid malignant peripheral nerve sheath tumor (C47.0 C47.6, C47.8, C47.9) 9560/1 Melanotic schwannoma (C72.4, C72.5)
12 /N 9741/1 Indolent systemic mastocytosis N
Effective January 1, 2018 ICD O 3 codes, behaviors and terms are site specific
Effective January 1, 2018 codes, behaviors and terms are site specific /N 8551/3 Acinar adenocarcinoma (C34. _) Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3
2018 ICD-O-3 Updates in Table Format with Annotation for Reference
Status Histology Description (this may be preferred term or a synonym) Report Comments New term 8010 3 Urachal carcinoma (C65.9, C66.9, C67._, C68._) New term 8013 3 Combined large cell neuroendocrine
2 Berkeley Street, Suite 403, Toronto, Ontario M5A 2W3 Visit us at: Tel: Fax:
E-Path A.I. Engine Knowledge Base Enhancements Version 1.0.0.29 April 1, 2018 The major enhancements in the E-Path Knowledge Base from versions 1.0.0.28 through 1.0.0.29 are as follows: 1. Addition/modification
Summary NAACCR: What you need to know for 2017 Version 1.1. March ICD-O-3 Histologies. Reportability There are no reportability changes in 2017.
Summary NAACCR: What you need to know for 2017 Version 1.1. March 2017 ICD-O-3 Histologies 2.1 New Terms and Codes Not Yet Implemented ICD-O-3 s and terms effective for 2015 was postponed due to CSv2 software
S2199 S2200. * Speaker's diagnosis 78
98 21 2 14 13:30 * Speaker's diagnosis 78 S2199 Meningioma 48 Papillary meningioma * 30 Angiomatous meningioma 15 Ependymoma 12 Papillary ependymoma 6 Anaplastic ependymoma 2 Cellular ependymoma 1 Hemangioblastoma
2018 Updates to National Standards
2018 Updates to National Standards 1 F C D S A N N U A L C O N F E R E N C E O R L A N D O, F L O R I D A 7 / 2 6 / 2 0 1 7 S T E V E N P E A C E, C T R ICD-O-3 New Histology Codes ICD-O-3 Behavior Changes
Appendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
ICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31
R=Rare Tier Tumour ICD-O Topography code ICD-O Morphology code EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES R 2 Squamous cell carcinoma with variants of nasal cavity and sinuses C30.0, C3 C30.0, C3 8000,
Contents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology
Contents Part I Introduction 1 General Description... 3 1.1 Introduction... 3 1.2 Incidence and Prevalence... 5 1.3 Predisposing and Genetic Factors... 8 References... 16 2 Natural History: Importance
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Eight Groups are Revised for 2018 Head & Neck Colon (includes rectosigmoid and rectum for cases diagnosed 1/1/2018 forward) Lung (2018 Draft not yet
incidence rate x 100,000/year
Tier R=rare C=common Cancer Entity European crude and age adjusted incidence by cancer, years of diagnosis 2000 and 2007 Analisys based on 83 population-based cancer registries * applying the European
CODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence
Rare Breast Tumours 1. Breast Tumours 1.1 General Results Table 1. Epithelial Tumours of Breast: Incidence, Trends, Survival Flemish Region 2001-2010 Incidence Trend Survival Females EAPC Relative survival
4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
Lung Tumor Cases: Common Problems and Helpful Hints
Lung Tumor Cases: Common Problems and Helpful Hints Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona Society of Pathologists
* Speaker's diagnosis
* Speaker's diagnosis Creutzfeldt-Jacob disease(cjd) 5 Prion disease( Creutzfeldt-Jakob disease ) 3 Extrapontine myelinolytis 5 Subacute sclerosing panencephalitis (SSPE) 5 Central pontine myelinolysis
Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
BMaP-3 Cancer Database. Aggregate Data File
BMaP-3 Cancer Database Aggregate Data File Contents BMaP-3 Cancer Database... 1 Aggregate Data File... 1 Frequency Tables... 2 Institution... 2 Year_First_Contact... 2 Primary_Site... 3 Sex... 3 Race...
Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact
Vulva Inflammatory Disorders Lichen Planus Fixed Drug Eruption Erythema Multiforme Plasmacytosis Mucosae (Zoon) Lichen Sclerosus Allergic Contact Dermatitis Psoriasis Lichen Simplex Chronicus Foreign Body
S Y M P O S I U M P R O G R A M
Dear colleagues, dear friends We would like to cordially welcome you to the 10 th International Arkadi M. Rywlin International Pathology Slide Seminar in Anatomic Pathology to be held in Split, Croatia.
Supplementary Information
Rise in Glioblastoma Multiforme incidence in England 1995 2015 suggests an adverse environmental or lifestyle factor Alasdair Philips, Denis L Henshaw, Graham Lamburn, Michael J O Carroll Supplementary
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
Differential Diagnosis of Oral Masses. Palatal Lesions
Differential Diagnosis of Oral Masses Palatal Lesions Palatal Masses Periapical Abscess Torus Palatinus Mucocele Lymphoid Hyperplasia Adenomatous Hyperplasia Benign Salivary Neoplasms Malignant Salivary
GUIDELINES FOR ICD-O-3 UPDATE IMPLEMENTATION Effective January 1, 2014
North American Association of Central Cancer Registries, Inc. GUIDELINES FOR ICD-O-3 UPDATE IMPLEMENTATION Effective January 1, 2014 Prepared by the NAACCR ICD-O-3 Update Implementation Work Group December
Methoden / Methods inc. ICCC-3 105
Methoden / Methods inc. ICCC-3 105 Internationale Klassifikation der Krebserkrankungen bei Kindern (ICCC-3) Zuordnung von ICD-O-3-Codes für Morphologie und Topographie zu diagnostischen Kategorien International
Protocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Version: BreastInvasive 1.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of
Normal endometrium: A, proliferative. B, secretory.
Normal endometrium: A, proliferative. B, secretory. Nội mạc tử cung Nội mạc tử cung Cyclic changes in endometrium.. Approximate relationship of useful microscopic changes. Arias-Stella reaction in endometrial
Surveys and Anatomic Pathology Education Programs
Surveys and Anatomic Pathology Education Programs Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2017 Participant Summary 2017 College of American Pathologists. The College does not permit
FINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
Minimally invasive adenocarcinoma. 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS)
Minimally invasive adenocarcinoma 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS) 2b lepidic acinar 2c papillary micropapillary solid 2d cribriform
Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
Disclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
Pathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP
What is New in the 2015 WHO Lung Cancer Classification? Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University, Canada Pulmonary Pathologist and Cytopathologist, QEII HSC Senior
SUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry
Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry April 2015 2015 Data Changes New Data Items Revised Data Items ICD-0-3 Reportability Change New ICDO Terms and Codes SEER
2007 Multiple Primary and
2007 Multiple Primary and Histology Coding Rules Beyond the Basics Florida Cancer Data System Annual Conference Tampa, FL July 26,2007 Steven Peace, CTR Westat Carol Johnson, CTR NCI SEER Peggy Adamo,
Spindle Cell Lesions Of The Breast. Emad Rakha Professor of Breast Pathology and Consultant Pathologist
Spindle Cell Lesions Of The Breast Emad Rakha Professor of Breast Pathology and Consultant Pathologist * SCLs comprise a wide spectrum of diseases, ranging from reactive processes to aggressive malignant
Neoplasias Quisticas del Páncreas
SEAP -Aproximación Práctica a la Patología Gastrointestinal- Madrid, 26 de mayo, 2006 Neoplasias Quisticas del Páncreas Gregory Y. Lauwers, M.D. Director, Service Massachusetts General Hospital Harvard
Surveys and Anatomic Pathology Education Programs
Surveys and Anatomic Pathology Education Programs Performance Improvement Program in Surgical Pathology PIP/PIPW-B 2018 Participant Summary 2018 College of American Pathologists. The College does not permit
North American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for Version 1.1
North American Association of Central Cancer Registries, Inc. (NAACCR) What You Need to Know for 2017 Version 1.1 January 2017 Revised March 2017 Table of Contents 1 Introduction... 3 2 ICD-O-3 Histologies...
CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY
CURRICULUM FOR THE BREAST PATHOLOGY ROTATION UNIVERSITY OF FLORIDA DEPARTMENT OF PATHOLOGY JULY, 2003 The following is a conceptual curriculum and set of guidelines for Pathology Residents on the Breast
Appendix E SEER Program Coding and Staging Manual DRAFT Reportable Examples
Appendix E1 2018 SEER Program Coding and Staging Manual DRAFT Reportable Examples Malignant # Diagnosis/Condition Notes 1 Atypical fibroxanthoma (superficial malignant fibrous histiocytoma) 2 Positive
SHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1
MPH s 11/8/07 Other s 1 Table 2 Continued Use this two-page table to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the
Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
Rare cancers are those with an incidence rate 6/100,000
Rare cancers are those with an incidence rate 6/100,000 Layer Tumour Rate x 100,000 Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES 0.44 3,594 2 Squamous cell carcinoma and variants of the
CANCER REGISTRY 2002
2 National Cancer Institute Department of Medical Services Ministry of Public Health Thailand Edited by Pattarawin Attasara, M.D. ISSN 974-7980-57-6 NATIONAL INSTITUTE STAFFS Consultant : Editor : Office
04/09/2018. Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances
Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory
Salivary Glands 3/7/2017
Salivary Glands 3/7/2017 Goals and objectives Focus on the entities unique to H&N Common board type facts Information for your future practice Salivary Glands Salivary Glands Major gland. Paratid. Submandibular.
S2326. Paucicellular myxoid liposarcoma 1 Histiocytic sarcoma 1 Alveolar soft part sarcoma 1 Perivascular epithelioid cell tumor (PEComa) 1
S2325 Encephalitis 21 Encephalitis 4 Cerebritis 1 Meningoencephalitis 4 Acute disseminated encephalomyelitis 2 Acute encephalitis(virus) 1 Herpes simplex encephalitis* 2 Encephalitis, viral infection?
The European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
Diagnostically Challenging Cases in Gynecologic Pathology
Diagnostically Challenging Cases in Gynecologic Pathology Eric C. Huang, M.D., Ph.D. Department of Pathology and Laboratory Medicine University of California, Davis Medical Center Case 1 Presentation 38
Layer Tumour Rate Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES Squamous cell carcinoma and variants of the Nasal Cavity
Layer Tumour Rate Patients 1 EPITHELIAL TUMOURS OF THE NASAL CAVITY and SINUSES 0.471 3060 2 Squamous cell carcinoma and variants of the Nasal Cavity and Sinuses 0.37 2615 3 Squamous carcinoma 0.24 1708
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid.
Gross appearance of peritoneal cysts. They have a thin, translucent wall and contain a clear fluid. So-called multicystic benign mesothelioma. A, Gross appearance. So-called multicystic benign mesothelioma.
VULVAR CARCINOMA. Page 1 of 5
VULVAR CARCINOMA EXAMPLE OF A VULVAR CARCINOMA USING PROPOSED TEMPLATE Case: Invasive squamous cell carcinoma arising in D-VIN Tumor in left labia major Left partial vaginectomy and sentinel lymph node
57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
SUPPLEMENTARY INFORMATION
VOLUME: 1 ARTICLE NUMBER: 0027 In the format provided by the authors and unedited. Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy
Enterprise Interest None
Enterprise Interest None What are triple negative breast cancers? A synopsis of their histological patterns Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology,
Detailed Table of Contents
Detailed 1 Immunostains: Introduction... 1 Natasha Rekhtman and Justin Bishop General Background... 1 Applications of Immunohistochemistry in Anatomic Pathology... 1 Markers of Differentiation at a Glance...
ANNUAL CANCER REGISTRY REPORT-2015
CANCER STATISTICS Distribution of neoplasms ANNUAL CANCER REGISTRY REPORT-2015 Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Hina Asif, Adna Atif, Farhana Badar Of a total of 5,924 new neoplasms diagnosed
WHO 2017: New Classification of Head and Neck Tumours
WHO 2017: New Classification of Head and Neck Tumours Ilmo Leivo Department of Pathology University of Turku & Turku University Hospital FINLAND Suomen IAP Aulanko 18.05.2018 WHO 2017 New entities Simplification
Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
ANNUAL CANCER REGISTRY REPORT-2016, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN
ANNUAL CANCER REGISTRY REPORT-2016, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Ain ul Quader, Hina Asif, Adna Atif, Mehwish Waseem,
of 20 to 80 and subsequently declines [2].
![of 20 to 80 and subsequently declines [2].](/thumbs/80/81450506.jpg "of 20 to 80 and subsequently declines [2].")
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
Pancreatic Cytopathology: The Solid Neoplasms
Pancreatic Cytopathology: The Solid Neoplasms Syed Z. Ali, M.D. Professor of Pathology and Radiology Director of Cytopathology The Johns Hopkins Hospital Baltimore, Maryland Pancreatic Cytopathology: Past,
Recent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
FINALIZED SEER SINQ QUESTIONS
0066 Source 1: 2016 SEER Manual pgs: 78 Notes: Primary Site Primary Site/Corpus uteri: Is the primary site C541 (endometrium) or C543 (uterine fundus) when the histology states endometrial adenocarcinoma,
Molecular pathology in soft tissue tumors. Sylvia Höller Pathologie
Molecular pathology in soft tissue tumors Sylvia Höller Pathologie When do we perform molecular testing? Morphology and IHC are not clearly fitting with an entity some translocations are entity specific
Case year female. Routine Pap smear
Case 1 57 year female Routine Pap smear Diagnosis? 1. Atypical glandular cells of unknown significance (AGUS) 2. Endocervical AIS 3. Endocervical adenocarcinoma 4. Endometrial adenocarcinoma 5. Adenocarcinoma
Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/
Molecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland
Molecular Diagnostics of Head and Neck Tumors Justin A. Bishop, M.D. Associate Professor of Pathology The Johns Hopkins University Baltimore, Maryland Two Main Topics Molecular insights in salivary gland
INDEX. in this web service Cambridge University Press
abscess. See also subareolar abscess acute mastitis, 44 lactational/puerperal mastitis, 55 mammary tuberculosis, 42 tuberculous, 43 adeno gastric, 198, 200 invasive, 157 lung, 197, 200 prostatic, 199 200
Financial disclosures
An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
Papillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
Breast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
FINALIZED SEER SINQ QUESTIONS
0067 MP/H Rules/Histology--Kidney: What is the correct histology for this diagnosis? See discussion. Procedure: Nephrectomy Laterality: Left Tumor type: SOLID VARIANT RENAL CELL CARCINOMA Nuclear grade:
Urinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
Index. J Juvenile hyaline fibromatosis, 27 Juvenile xanthogranuloma, 57 Juxta-articular myxoma, 152
A Adenomatoid tumor, 76, 77 Adipose tissue tumors benign tumors angiolipoma, 6 chondroid lipoma, 9 fibrolipoma, 5 hibernoma, 8 lipoblastoma, 9 lipoma (see Lipoma) myelolipoma, 6 pleomorphic lipoma, 8 spindle
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual Rajal B. Shah, M.D. Director, Urologic Pathology SHAHR6@ccf.org @rajalbshah
LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR
BREAST LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR HISTOLOGY LOBE: (10 in whole breast) LOBULE: (many per lobe) ACINUS/I, aka ALVEOLUS/I: (many per lobule) DUCT(S): INTRA- or
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct
ANNUAL CANCER REGISTRY REPORT-2017, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN
ANNUAL CANCER REGISTRY REPORT-2017, OF THE SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTER, PAKISTAN Shahid Mahmood, Raqib Faraz, Aneel Yousaf, Ain ul Quader, Hina Asif, Adna Atif, Lubna Nadeem,
Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
ICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
ICD-O-3 UPDATES - PENDING
ICD-O-3 UPDATES - PENDING FCDS Annual Meeting July 26, 2013 Sunrise, Florida Steven Peace, CTR ICD-O-3 Work Group ICD-O-3 WORK GROUP Name April Fritz, CTR Lynn Ries, MS Lois Dickie, CTR Linda Mulvihill,
Diagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
CANCER REGISTRY 2004
2 National Cancer Institute Department of Medical Services Ministry of Public Health Thailand Edited by Pattarawin Attasara, M.D. ISSN 974-7980-57-6 NATIONAL INSTITUTE STAFFS Consultant : Editor : Office
EQA Circulation 43 Educational Cases
EQA Circulation 43 Educational Cases E1-E2 Monica Agarwal Monklands Hospital E1 38 yrs male Submandibular gland tumour E1 Formal excision following diagnosis of poorly differentiated carcinoma on core
Update in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016
Update in Salivary Gland Pathology Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016 Objectives Review the different appearances of a selection of salivary gland tumor types Establish
Ludvik R. Donner, MD, PhD Reference List
Gopal S, Marcussen S, Dobin SM, Koss W, Donner LR. Primary myeloid sarcoma of the testicle with t(15;17). Cancer Genetics and Cytogenetics; 157[2]:148-150. 2005 Donner LR, Marcussen S, Dobin SM. A clonal
Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
Sentinel nodes. Location: Location: S1.04 Principal clinician. G1.01 Record other relevant information. S2.01 Number of specimens submitted
Invasive Breast Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth DD MM YYYY
Carcinoma of unknown primary origin (CUP) is defined
REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin